The University of Southampton
University of Southampton Institutional Repository

CD40 ligation for immunotherapy of solid tumours

CD40 ligation for immunotherapy of solid tumours
CD40 ligation for immunotherapy of solid tumours
Tumour vaccines provide an important focus of current cancer research and are often based on the premise that although T-cells do respond naturally to certain tumours, this is usually weak and therefore ineffective at controlling disease. An integral and necessary part of a T-cell immune response involves triggering of CD40 on antigen-presenting cells (APC) by its ligand, CD154, on responding T helper (Th) cells. Furthermore, cytotoxic responses to tumours may fail because the Th-cell response is inadequate and unable to provide CD40 stimulation of APC. Growing evidence shows that stimulating APC with soluble CD40L or an agonistic anti-CD40 mAb can, at least in part, replace the need for Th cells and generate APC that are capable of priming cytotoxic T lymphocytes (CTL). The aim of this study was to investigate whether a range of solid tumours (CD40?) could be treated with anti-CD40 mAb. It was found that this treatment was effective, and correlated with the intrinsic immunogenicity and aggressiveness of the tumours. The mAb could be delivered locally or at a distal site, but increased antigen load provided by irradiated tumour cells added little to the effectiveness of the treatment. T-cells were required since cytokine (interferon-?) and CTL activity were demonstrated following treatment and the therapeutic efficacy was lost in nude mice. In addition, depletion of CD8+ cells abrogated protection whilst depletion of CD4+ cells had no effect. This study demonstrates that solid CD40? tumours are sensitive to anti-CD40 mAb therapy and that the response bypasses the need for Th cells.
tumour immunotherapy, CD40 ligation, monoclonal antibody, T-cell response
0022-1759
139-147
Todryk, Stephen M.
3b7d8dd4-db91-47e0-8218-65a9fe220838
Tutt, Alison L.
46ce577b-aea1-412d-84ea-fc4dab794469
Green, Michael H.A.
d88f7cfd-8b8b-4cd7-b874-edacfba3a541
Smallwood, J.A.
46f8b12a-6df1-41fa-a2d2-220789b51828
Halanek, Nicole
3abbeaa7-fd7a-4a2e-91a6-14387aff6a6e
Dalgleish, Angus G.
4403a69b-4f19-4329-a232-baa1bbdba06f
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Todryk, Stephen M.
3b7d8dd4-db91-47e0-8218-65a9fe220838
Tutt, Alison L.
46ce577b-aea1-412d-84ea-fc4dab794469
Green, Michael H.A.
d88f7cfd-8b8b-4cd7-b874-edacfba3a541
Smallwood, J.A.
46f8b12a-6df1-41fa-a2d2-220789b51828
Halanek, Nicole
3abbeaa7-fd7a-4a2e-91a6-14387aff6a6e
Dalgleish, Angus G.
4403a69b-4f19-4329-a232-baa1bbdba06f
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded

Todryk, Stephen M., Tutt, Alison L., Green, Michael H.A., Smallwood, J.A., Halanek, Nicole, Dalgleish, Angus G. and Glennie, Martin J. (2001) CD40 ligation for immunotherapy of solid tumours. Journal of Immunological Methods, 248 (1-2), 139-147. (doi:10.1016/S0022-1759(00)00349-5).

Record type: Article

Abstract

Tumour vaccines provide an important focus of current cancer research and are often based on the premise that although T-cells do respond naturally to certain tumours, this is usually weak and therefore ineffective at controlling disease. An integral and necessary part of a T-cell immune response involves triggering of CD40 on antigen-presenting cells (APC) by its ligand, CD154, on responding T helper (Th) cells. Furthermore, cytotoxic responses to tumours may fail because the Th-cell response is inadequate and unable to provide CD40 stimulation of APC. Growing evidence shows that stimulating APC with soluble CD40L or an agonistic anti-CD40 mAb can, at least in part, replace the need for Th cells and generate APC that are capable of priming cytotoxic T lymphocytes (CTL). The aim of this study was to investigate whether a range of solid tumours (CD40?) could be treated with anti-CD40 mAb. It was found that this treatment was effective, and correlated with the intrinsic immunogenicity and aggressiveness of the tumours. The mAb could be delivered locally or at a distal site, but increased antigen load provided by irradiated tumour cells added little to the effectiveness of the treatment. T-cells were required since cytokine (interferon-?) and CTL activity were demonstrated following treatment and the therapeutic efficacy was lost in nude mice. In addition, depletion of CD8+ cells abrogated protection whilst depletion of CD4+ cells had no effect. This study demonstrates that solid CD40? tumours are sensitive to anti-CD40 mAb therapy and that the response bypasses the need for Th cells.

This record has no associated files available for download.

More information

Published date: 2001
Keywords: tumour immunotherapy, CD40 ligation, monoclonal antibody, T-cell response

Identifiers

Local EPrints ID: 26639
URI: http://eprints.soton.ac.uk/id/eprint/26639
ISSN: 0022-1759
PURE UUID: 598a4d3e-df48-4567-a797-688294638e54

Catalogue record

Date deposited: 24 Apr 2006
Last modified: 15 Mar 2024 07:12

Export record

Altmetrics

Contributors

Author: Stephen M. Todryk
Author: Alison L. Tutt
Author: Michael H.A. Green
Author: J.A. Smallwood
Author: Nicole Halanek
Author: Angus G. Dalgleish

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×